- Home
- ANIP
as 03-28-2025 4:00pm EST
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid dose products. Its areas of product development include narcotics, oncolytic, hormones and steroids, and complex formulations involving extended release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.
| Founded: | 2001 | Country: | United States |
| Employees: | N/A | City: | BAUDETTE |
| Market Cap: | 1.2B | IPO Year: | N/A |
| Target Price: | $79.75 | AVG Volume (30 days): | 374.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.04 | EPS Growth: | N/A |
| 52 Week Low/High: | $52.50 - $70.00 | Next Earning Date: | 05-09-2025 |
| Revenue: | $614,376,000 | Revenue Growth: | 26.20% |
| Revenue Growth (this year): | 26.8% | Revenue Growth (next year): | 6.89% |
Stock Insider Trading Activity of ANI Pharmaceuticals Inc. (ANIP)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Davis Krista | ANIP | SVP, CHIEF HR OFFICER | Mar 19 '25 | Sell | $65.00 | 1,866 | $121,290.00 | 64,659 | |
| Cook Meredith | ANIP | SR. VP, GENERAL COUNSEL & SEC. | Mar 13 '25 | Sell | $63.33 | 400 | $25,332.00 | 80,545 | |
| Davis Krista | ANIP | SVP, CHIEF HR OFFICER | Mar 7 '25 | Sell | $60.86 | 1,000 | $60,860.00 | 64,659 | |
| Gutwerg Ori | ANIP | SVP, GENERICS | Mar 5 '25 | Sell | $60.02 | 5,384 | $323,049.00 | 94,092 | |
| Davis Krista | ANIP | SVP, CHIEF HR OFFICER | Feb 21 '25 | Sell | $60.20 | 1,000 | $60,200.00 | 64,659 | |
| Cook Meredith | ANIP | SR. VP, GENERAL COUNSEL & SEC. | Feb 12 '25 | Sell | $59.54 | 400 | $23,816.00 | 80,545 | |
| Cook Meredith | ANIP | SR. VP, GENERAL COUNSEL & SEC. | Jan 13 '25 | Sell | $53.92 | 400 | $21,568.00 | 80,545 |
Latest ANI Pharmaceuticals Inc. News
ANIP Breaking Stock News: Dive into ANIP Ticker-Specific Updates for Smart Investing
Argus Research
5 days ago
ANIP: Raising target price to $70.00
Zacks
6 days ago
5 Top-Ranked Mid-Cap Stocks to Buy for a Stellar Portfolio
Zacks
7 days ago
Is ANI (ANIP) a Solid Growth Stock? 3 Reasons to Think "Yes"
Zacks
7 days ago
Wall Street Analysts Think ANI (ANIP) Could Surge 26.83%: Read This Before Placing a Bet
Zacks
7 days ago
Should You Buy ANI Pharmaceuticals (ANIP) After Golden Cross?
Zacks
10 days ago
Is Corcept Therapeutics (CORT) Stock Outpacing Its Medical Peers This Year?
MT Newswires
12 days ago
Ani Pharmaceuticals Launches Nitazoxanide Tablets for Treating Diarrhea
GlobeNewswire
12 days ago
ANI Pharmaceuticals Announces the Launch of Nitazoxanide Tablets
Compare ANIP vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ANIP ANI Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.